Celgene Corporation Overview
Pro stress-test →Celgene Corporation is an American pharmaceutical company that makes cancer and immunology drugs. The company is a subsidiary of Bristol Myers Squibb (BMS) since its acquisition in 2019. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias.
Strategic Profile
Pro stress-test →As of February 2026, Celgene's annual revenue is estimated to be $21B. The company is developing therapies for multiple myeloma, inflammatory diseases, and various forms of cancer, with its lead molecule BCMA CAR T used for treating multiple myeloma in phase II clinical study. As a wholly-owned subsidiary integrated into Bristol Myers Squibb's oncology and immunology divisions, Celgene remains a critical driver of BMS's cancer therapeutics portfolio.
Competitive Landscape
Pro stress-test →Top competitors include Kite Pharma, Juno Therapeutics and ImmunoACT. Celgene competes in the immunotherapy and cancer drug markets alongside major pharma innovators developing CAR-T therapies and next-generation immuno-oncology agents. Within Bristol Myers Squibb's portfolio, Celgene's oncology franchise complements BMS's broader immunology and cardiovascular platforms.
Industry Context
Celgene Corporation operates in Oncology and immunotherapy pharmaceuticals.
Key facts
Founded: 1986 · Headquarters: Summit, New Jersey, US · Employees: 2,100 · Revenue: $21B